Ultragenyx Pharmaceutical (RARE) stock is back in focus after a federal securities class action challenged how it communicated Phase III trial results for setrusumab in osteogenesis imperfecta, following study failures and announced expense reductions.

At a share price of US$22.21, Ultragenyx has seen a 1 day share price return of 2.76% decline and a 90 day share price return of 38.65% decline. The 1 year total shareholder return of 44.87% decline suggests momentum has been fading as the trial setbacks and class action filings reshaped investors’ view of risk and potential.

If this legal and trial news has you rethinking your biotech exposure, it could be a good moment to scan other opportunities in healthcare, starting with our list of 34 healthcare AI stocks.

With the shares down sharply over 1 year and trading at a steep discount to some valuation estimates, you have to ask: is Ultragenyx now being penalized too heavily for trial risk, or is the market already pricing in its future potential?

Most Popular Narrative: 65.3% Undervalued

At a last close of $22.21 versus a narrative fair value of about $64.00, the most followed view sees a wide gap that hinges on future gene therapy execution and margin expansion.

Ultragenyx's clinical pipeline is advancing with five Phase III programs (including UX143 and GTX-102), multiple BLA submissions expected in the coming quarters, and near-term Phase III data readouts (notably for UX143 in OI by year-end and GTX-102 in Angelman syndrome in 2026) serving as upcoming value inflection points that can diversify and significantly accelerate the company's revenue base.

Want to see what kind of revenue curve and margin profile that story assumes? The narrative leans on steep compounding, a sharp loss to profit swing, and a punchy valuation multiple to get to that fair value mark.

Result: Fair Value of $64.00 (UNDERVALUED)

However, this hinges on clinical and regulatory success, and setbacks on programs like UX111 or DTX401 could quickly undercut the profit and valuation story that investors are modeling.

Another View: Market Ratios Send A Different Signal

While our DCF model flags Ultragenyx as trading at a large discount to an estimated future cash flow value of about $259.21 per share, the simple P/S check is less generous. At 3.2x sales versus a fair ratio of 2.2x, the stock screens as expensive on this metric. With the US Biotechs industry at 12.4x and peers at 15.8x, you are looking at a name that appears cheap relative to other companies but rich relative to where the fair ratio suggests the market could move. Which anchor do you trust more?

Next Steps

If the mix of risks and optimism here feels finely balanced, take a closer look at the underlying data yourself and decide quickly where you stand. Then use our breakdown of 2 key rewards and 2 important warning signs to round out your view.

Looking for more investment ideas?

If this story has sharpened your focus on risk and reward, do not stop here. Use the screener to hunt for stronger setups that fit your own style.

• Target resilient income by checking companies that show up as 14 dividend fortresses and see which payers stand out on yield and stability.
• Pursue value opportunities through screener containing 23 high quality undiscovered gems and spot names that have strong fundamentals but limited market attention.
• Prioritise capital protection first by reviewing 67 resilient stocks with low risk scores and compare businesses that screen well on balance sheet strength and risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.